Xie Ning Wu1, Guo Jin Wang. 1. Department of Hepato-Gastroenterology, Shanghai First People's Hospital, Shanghai, China.
Abstract
OBJECTIVE: Viral hepatitis B is a worldwide public health problem; in China, chronic hepatitis B patients account for 30-40 million people and chronic hepatitis C accounts for 16% of all chronic hepatitis patients. Interferon-alpha (IFNalpha) is rather expensive and has many serious side-effects, which makes practitioners prudent in its use. METHOD/ RESULTS: A multicenter study held in China showed that the negative seroconversion of HBV DNA by oxymatrine and IFNalpha-1b was 42.3% and 40.7%, respectively, and that of HBeAg was 36.5% and 38.9%, respectively, after 3 months treatment with each in patients with chronic hepatitis. CONCLUSIONS: Oxymatrine has a similar efficacy to IFNalpha, but with no adverse effects apart from slight injection pain, and it is much less expensive.
OBJECTIVE:Viral hepatitis B is a worldwide public health problem; in China, chronic hepatitis B patients account for 30-40 million people and chronic hepatitis C accounts for 16% of all chronic hepatitispatients. Interferon-alpha (IFNalpha) is rather expensive and has many serious side-effects, which makes practitioners prudent in its use. METHOD/ RESULTS: A multicenter study held in China showed that the negative seroconversion of HBV DNA by oxymatrine and IFNalpha-1b was 42.3% and 40.7%, respectively, and that of HBeAg was 36.5% and 38.9%, respectively, after 3 months treatment with each in patients with chronic hepatitis. CONCLUSIONS:Oxymatrine has a similar efficacy to IFNalpha, but with no adverse effects apart from slight injection pain, and it is much less expensive.
Authors: Ning Liang; De Zhao Kong; Si Si Ma; Chun Li Lu; Ming Yang; Lu Da Feng; Chen Shen; Ruo Han Diao; Ling Jun Cui; Xing Yu Lu; Dimitrinka Nikolova; Janus C Jakobsen; Christian Gluud; Jian Ping Liu Journal: Cochrane Database Syst Rev Date: 2019-04-03
Authors: Mohammad K Parvez; Mohammed S Al-Dosari; Md Tabish Rehman; Adnan J Al-Rehaily; Ali S Alqahtani; Mohammad F Alajmi Journal: Saudi Pharm J Date: 2022-02-07 Impact factor: 4.562